Form 8-K Contineum Therapeutics, For: Nov 20
Contineum Therapeutics, Inc. - Common stock (CTNM)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
CTNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTNM alerts
High impacting Contineum Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CTNM
News
- Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare ConferenceBusiness Wire
- Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Robert W. Baird from $16.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $22.00. They now have an "outperform" rating on the stock.MarketBeat
- Contineum falls after missing main goals in multiple sclerosis trial [Seeking Alpha]Seeking Alpha
- Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) [Yahoo! Finance]Yahoo! Finance
CTNM
Earnings
- 5/14/25 - Miss
CTNM
Sec Filings
- 11/4/25 - Form SCHEDULE
- 10/30/25 - Form 10-Q
- 10/30/25 - Form 8-K
- CTNM's page on the SEC website